TNBC

Oncology·MeSH: Triple Negative Breast Neoplasms

19 drugs in development·12 companies·5 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
trodelvy	Immunome Inc. (IMNM)

Phase 3(2)

Drug	Company
Abraxane	Merus N.V. (MRUS)
sacituzumab govitecan	IMMUNOMEDICS INC (IMMU)

Phase 2(5)

Drug	Company
abv-1501	ABVC BIOPHARMA, INC. (ABVC)
Leronlimab	CytoDyn Inc. (CYDY)
Long-acting leronlimab	CytoDyn Inc. (CYDY)
Maximum Tolerated Dose of leronlimab	CytoDyn Inc. (CYDY)
Sintilimab	Merus N.V. (MRUS)

Phase 1(9)

Drug	Company
alpha-lactalbumin breast cancer vaccine	Anixa Biosciences Inc (ANIX)
BBI-355	Boundless Bio, Inc. (BOLD)
BBI-825	Boundless Bio, Inc. (BOLD)
Breast cancer vaccine (alpha-lactalbumin)	Anixa Biosciences Inc (ANIX)
Breast cancer vaccine (α-lactalbumin)	Anixa Biosciences Inc (ANIX)
CLR 121125	Cellectar Biosciences, Inc. (CLRB)
CTX-8371	Compass Therapeutics, Inc. (CMPX)
erlotinib	Boundless Bio, Inc. (BOLD)
ivac_w_bre1_uid	BioNTech SE (BNTX)

Phase 1/Phase 2(2)

Drug	Company
l-nmma	Galera Therapeutics, Inc. (GRTX)
zn-telomir	Telomir Pharmaceuticals, Inc. (TELO)

BioSniper tracks 19 drugs in development for TNBC across 12 companies.

There are 5 clinical trials targeting TNBC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.